Specializing in the development of botanical drugs for the treatment of dependencies and addictions, the Montpellier-based biotech NFL Biosciences (15 employees) announces the appointment of Bruno Lafont, until now Deputy Managing Director, to the position of CEO. He is responsible for steering the structuring and clinical and industrial development of the company, and for finding the best financing for this purpose. It also remains, moreover, one of the main shareholders with nearly 9% of the capital. At the same time, Ignacio Faus, who previously held the position of CEO, becomes Deputy Managing Director. This reversal of functions within the governance of NFL Biotech was decided to prepare its passage into phase III of clinical development and the registration of its priority drug candidate for smoking cessation.
